澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

PARADIGM BIOPHARMACEUTICALS

0.260

-0.010-3.70%

成交量：162.87万

成交额：42.86万

市值：1.14亿

市盈率：-4.36

高：0.270

开：0.265

低：0.260

收：0.270

52周最高：0.505

52周最低：0.255

股本：4.39亿

流通股本：3.53亿

量比：1.86

换手率：0.46%

股息：- -

股息率：- -

每股收益(TTM):-0.060

每股收益(LYR):-0.060

净资产收益率：-81.66%

总资产收益率：-55.11%

市净率：5.39

市盈率(LYR):-4.36

数据加载中...

总览公司新闻资讯公告

Paradigm Biopharmaceuticals Ltd签署口服PPS与Cox-2抑制剂组合的约束性兽药许可与供应协议

PARADIGM BIOPHARMACEUTICALS有望从Avet获得高达100万美元的开发里程碑款项

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PAR.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.26,"timestamp":1772169120000,"preClose":0.27,"halted":0,"volume":1628717,"delay":0,"changeRate":-0.03703703703703707,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":439254435,"eps":-0.059699,"marketStatus":"休市中","change":-0.01,"latestTime":"02-27 16:12:00 AEDT","open":0.265,"high":0.27,"low":0.26,"amount":428589,"amplitude":0.037037,"askPrice":0.27,"askSize":102095,"bidPrice":0.26,"bidSize":394167,"shortable":3,"etf":0,"ttmEps":-0.059699,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1772406000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.27,"openAndCloseTimeList":[[1772146800000,1772168400000]],"volumeRatio":1.8626161390012517,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-55.11%","roe":"-81.66%","lyrEps":-0.059684,"volumeRatio":1.8626161390012517,"shares":439254435,"dividePrice":0,"high":0.27,"amplitude":0.037037,"preClose":0.27,"low":0.26,"week52Low":0.255,"pbRate":"5.39","psRate":"6838.69","week52High":0.505,"institutionHeld":0,"latestPrice":0.26,"committee":0.588544,"eps":-0.059699,"divideRate":0,"volume":1628717,"delay":0,"ttmEps":-0.059699,"open":0.265,"prevYearClose":0.34,"prevWeekClose":0.28,"prevMonthClose":0.305,"prevQuarterClose":0.34,"fiveDayClose":0.28,"twentyDayClose":0.305,"sixtyDayClose":0.38,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140711318","title":"Paradigm Biopharmaceuticals Ltd签署口服PPS与Cox-2抑制剂组合的约束性兽药许可与供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1140711318","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140711318?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 06:09","pubTimestamp":1770588550,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals Ltd（PAR.AU）已正式签署一项具有约束力的兽药许可与供应协议，该协议涉及口服PPS与Cox-2抑制剂的组合疗法。这一重要合作标志着公司在兽药领域迈出关键一步，为动物医疗市场带来创新治疗方案。协议的签署不仅强化了Paradigm在生物制药行业的战略布局，也为其产品管线的多元化发展注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"1127723459","title":"PARADIGM BIOPHARMACEUTICALS有望从Avet获得高达100万美元的开发里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1127723459","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127723459?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 06:09","pubTimestamp":1770588550,"startTime":"0","endTime":"0","summary":"PARADIGM BIOPHARMACEUTICALS宣布，其有资格从合作方Avet处获得最高达100万美元的开发里程碑付款。这笔款项的支付将与特定研发进展目标的达成直接挂钩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PAR.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}